SORAVTANSINE

Details

Stereochemistry	EPIMERIC
Molecular Formula	C42H60ClN3O15S3
Molecular Weight	978.585
Optical Activity	UNSPECIFIED
Defined Stereocenters	8 / 9
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12C[C@@](O)(NC(=O)O1)[C@]([H])(OC)\C=C\C=C(C)\CC3=CC(N(C)C(=O)C[C@]([H])(OC(=O)[C@H](C)N(C)C(=O)CCC(C)(C)SSCCC(C(O)=O)S(O)(=O)=O)[C@]4(C)O[C@H]4[C@@H]2C)=C(Cl)C(OC)=C3

InChI

InChIKey=GQSPYHXXAXFCRB-DSIKUUPMSA-N

InChI=1S/C42H60ClN3O15S3/c1-23-12-11-13-31(58-10)42(53)22-29(59-39(52)44-42)24(2)36-41(6,61-36)32(21-34(48)46(8)27-19-26(18-23)20-28(57-9)35(27)43)60-38(51)25(3)45(7)33(47)14-16-40(4,5)63-62-17-15-30(37(49)50)64(54,55)56/h11-13,19-20,24-25,29-32,36,53H,14-18,21-22H2,1-10H3,(H,44,52)(H,49,50)(H,54,55,56)/b13-11+,23-12+/t24-,25+,29+,30?,31-,32+,36+,41+,42+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C42H60ClN3O15S3
Molecular Weight	978.585
Charge	0
Count

Stereochemistry	EPIMERIC
Additional Stereochemistry	No
Defined Stereocenters	8 / 9
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://apps.who.int/iris/bitstream/handle/10665/275695/WHO-EMP-RHT-TSN-2018.1-eng.pdf?sequence=1&isAllowed=y | https://www.ncbi.nlm.nih.gov/pubmed/27889646 | https://www.ncbi.nlm.nih.gov/pubmed/28440955 | https://www.ncbi.nlm.nih.gov/pubmed/25826705

Soravtansine (DM4-SULFO-TBA), a maytansinoid derivative, is an antineoplastic agent. Antibody–maytansinoid conjugates (like Mirvetuximab soravtansine) are in clinical trials for the treatment of various cancers. Thus, Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that targets FRα (folate receptor alpha) for tumor-directed delivery of the maytansinoid DM4, a potent agent that induces mitotic arrest by suppressing microtubule dynamics.

Approval Year

PubMed

Title	Date	PubMed
Metabolites of antibody-maytansinoid conjugates: characteristics and in vitro potencies.	2015 Jun 1	25826705
Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.	2016 Dec	27889646
Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor α-targeting antibody-drug conjugate, in patients with solid tumors.	2017 Aug 15	28440955
A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer.	2018 Jan	29098867

Patents

Sample Use Guides

In Vitro Use Guide

In COLO205 cells, the IC50 values of DM4-SULFO-TBA was 26 pM, while in HT29 cells, the IC50 value was 22 pM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 06:22:44 GMT 2023` Edited by `admin` on `Sat Dec 16 06:22:44 GMT 2023`
Record UNII	6PON74J1XY
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SORAVTANSINE

Official Name

English

MAYTANSINE, N2'-(4-((3-CARBOXY-3-SULFOPROPYL)DITHIO)-4-METHYL-1-OXOPENTYL)-N2'-DEACETYL-

Systematic Name

English

SORAVTANSINE [USAN]

Common Name

English

DM-4-SULFO-TBA

Code

English

DM4-SULFO-TBA

Code

English

Code System Code Type Description

USAN

BC-77